Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.
暂无分享,去创建一个
D. Johns | D. Kirchhofer | J. Luyendyk | N. Mackman | B. Furie | A. Daugherty | B. Hubbard | P. Tobias | A. P. Owens | L. Curtiss | L. Rudel | R. Temel | Allison L. McDaniel | Stephanie M. Marshall | B. Furie | P. Moriarty | F. Passam | S. Nagarajan | S. Antoniak | Jianguo Wang | Julie C. Williams | J. Dutton
[1] Paul J. Harrison,et al. Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis , 2011, Nanomedicine : nanotechnology, biology, and medicine.
[2] A. Basten,et al. Faculty Opinions recommendation of Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation. , 2011 .
[3] N. Mackman,et al. Microparticles in Hemostasis and Thrombosis , 2011, Circulation research.
[4] T. Luther,et al. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. , 2010, Blood.
[5] J. Luyendyk,et al. Effect of low-density lipoprotein apheresis on plasma levels of apolipoprotein e4. , 2010, The American journal of cardiology.
[6] L. Bernier,et al. A new method for measurement of total plasma PCSK9: clinical applications , 2010, Journal of Lipid Research.
[7] K. Moore,et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer , 2009, Nature Immunology.
[8] D. Kirchhofer,et al. Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice , 2009, Journal of thrombosis and haemostasis : JTH.
[9] Andrew C. Li,et al. Lipoprotein Accumulation in Macrophages via Toll-Like Receptor-4-Dependent Fluid Phase Uptake , 2009, Circulation research.
[10] J. Freyssinet,et al. Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation. , 2009, Atherosclerosis.
[11] P. Libby,et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.
[12] E. Horváth-Puhó,et al. Arterial cardiovascular events, statins, low‐dose aspirin and subsequent risk of venous thromboembolism: a population‐based case‐control study , 2009, Journal of thrombosis and haemostasis : JTH.
[13] F. Rosendaal,et al. HMG‐CoA reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.
[14] A. Khorana,et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer , 2008, Journal of thrombosis and haemostasis : JTH.
[15] K. McCrae,et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. , 2008, The Journal of clinical investigation.
[16] Seppo Ylä-Herttuala,et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. , 2008, Cardiovascular research.
[17] P. Thampi,et al. Dietary homocysteine promotes atherosclerosis in apoE-deficient mice by inducing scavenger receptors expression. , 2008, Atherosclerosis.
[18] S. Hazen,et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype , 2007, Nature Medicine.
[19] F. Kronenberg,et al. Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[20] K. Stokes,et al. Tissue factor: a mediator of inflammatory cell recruitment, tissue injury, and thrombus formation in experimental colitis , 2007, The Journal of experimental medicine.
[21] E. Tremoli,et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. , 2007, Pharmacological research.
[22] Y. Castier,et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. , 2007, Journal of the American College of Cardiology.
[23] P. Libby,et al. Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering: A Potential Biomarker of Early Atherosclerosis Regression , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[24] K. Williams,et al. Cholesterol Enrichment of Human Monocyte/Macrophages Induces Surface Exposure of Phosphatidylserine and the Release of Biologically-Active Tissue Factor–Positive Microvesicles , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[25] Raimund Erbel,et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.
[26] C. Esmon. The interactions between inflammation and coagulation , 2005, British journal of haematology.
[27] G. Vilahur,et al. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering , 2005, Thrombosis and Haemostasis.
[28] H. Methe,et al. Statins Decrease Toll-Like Receptor 4 Expression and Downstream Signaling in Human CD14+ Monocytes , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[29] H. Methe,et al. Expansion of Circulating Toll-Like Receptor 4–Positive Monocytes in Patients With Acute Coronary Syndrome , 2005, Circulation.
[30] F. Peale,et al. A monoclonal antibody that inhibits mouse tissue factor function , 2005, Journal of thrombosis and haemostasis : JTH.
[31] M. Wolzt,et al. Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo , 2005, Circulation.
[32] Nigel Mackman,et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. , 2004, Blood.
[33] W. Sasiela,et al. High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial , 2004, Circulation.
[34] E. Oger,et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case–control study , 2004, Fundamental & clinical pharmacology.
[35] R. Rosenson. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. , 2004, Atherosclerosis.
[36] N. Mackman,et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. , 2004, Blood.
[37] T. Iwasaka,et al. Increased level of oxidized LDL-dependent monocytederived microparticles in acute coronary syndrome , 2003, Thrombosis and Haemostasis.
[38] M. Rosenfeld,et al. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. , 2003, Atherosclerosis.
[39] K. Moore,et al. Scavenger Receptors Class A-I/II and CD36 Are the Principal Receptors Responsible for the Uptake of Modified Low Density Lipoprotein Leading to Lipid Loading in Macrophages* , 2002, The Journal of Biological Chemistry.
[40] B. Furie,et al. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse , 2002, Nature Medicine.
[41] P. Libby,et al. Statins Reduce Inflammation in Atheroma of Nonhuman Primates Independent of Effects on Serum Cholesterol , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[42] E. Tremoli,et al. Fluvastatin Reduces Tissue Factor Expression and Macrophage Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits in the Absence of Lipid Lowering , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[43] F. Gruber,et al. Analysis of inflammatory gene induction by oxidized phospholipids in vivo by quantitative real-time RT-PCR in comparison with effects of LPS. , 2002, Vascular pharmacology.
[44] R. Westrick,et al. Deficiency of Tissue Factor Pathway Inhibitor Promotes Atherosclerosis and Thrombosis in Mice , 2001, Circulation.
[45] J. Witztum,et al. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. , 2001, Circulation.
[46] P. Libby,et al. An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro , 2001, Circulation.
[47] J. Witztum,et al. Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[48] R. Westrick,et al. Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[49] S. Basili,et al. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. , 2000, Atherosclerosis.
[50] M. Penn,et al. Native and Oxidized Low Density Lipoprotein Induction of Tissue Factor Gene Expression in Smooth Muscle Cells Is Mediated by Both Egr-1 and Sp1* , 1999, The Journal of Biological Chemistry.
[51] R. Ross. Atherosclerosis is an inflammatory disease , 1999 .
[52] D. Rader,et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. , 1999, The Journal of clinical investigation.
[53] F. Werf,et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. , 1998, Circulation.
[54] P. Carmeliet,et al. Low levels of tissue factor are compatible with development and hemostasis in mice. , 1998, The Journal of clinical investigation.
[55] S. Basili,et al. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia , 1997, The Lancet.
[56] E. Tremoli,et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[57] J. Fallon,et al. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[58] D. Waters,et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.
[59] S. Young,et al. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[60] K. Williams,et al. The response-to-retention hypothesis of early atherogenesis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[61] S. Kaul,et al. Altered vascular responses to platelets from hypercholesterolemic humans. , 1993, Circulation research.
[62] T. Bocan,et al. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel filtration chromatography. , 1991, Journal of lipid research.
[63] Haihua,et al. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. , 1991, The American journal of pathology.
[64] V. Armstrong,et al. Enhanced procoagulatory activity (PCA) of human monocytes/macrophages after in vitro stimulation with chemically modified LDL. , 1989, Atherosclerosis.
[65] Kathleen M. Smith,et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[66] J. Neaton,et al. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.
[67] E. Haber,et al. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. , 1983, Science.
[68] S. Kaul,et al. Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocyte-derived macrophages by oxidized low density lipoprotein. , 2011, Journal of atherosclerosis and thrombosis.
[69] Li Zhou,et al. Increased expression of Toll like receptor 4 on peripheral‐blood mononuclear cells in patients with coronary arteriosclerosis disease , 2006, Clinical and experimental immunology.
[70] T. Wakefield,et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. , 2005, Blood.
[71] Bernd R Binder,et al. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. , 2002, Blood.
[72] F. Bruni,et al. Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin , 2000, International journal of clinical & laboratory research.
[73] A. Chang,et al. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. , 1998, Blood.
[74] D. Steinberg,et al. Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.